The Real ROI of GLP-1s: A deep dive into third party-validated ROI models for approaching weight health care coverage at an organization

Employers are facing two very distinct approaches to addressing the full spectrum of weight health within their population: the “offensive” approach which usually tends to cover anti-obesity medications like GLP-1s, and the “defensive” approach which leans more conservatively in benefit coverage or addressing new weight treatments. These two strategies have their own risks and rewards—and most importantly, both have significant short-term and long-term effects on an organization’s healthcare costs and potential ROI.

Join us as we explore the only third party-validated ROI models for the employer market from the Santa Barbara Actuaries firm and what this means for organizations looking to expand or retract weight health care coverage for their population.